Goldman Sachs predicts that the introduction of Zepbound, a rival of Eli Lilly’s Wegovy, will contribute to the growth of the weight-loss drug market, making it worth $130 billion by 2030.
The weight-loss drug Zepbound, developed by Eli Lilly, is a new addition to the market. Goldman Sachs predicts that the anti-obesity drug market will reach a value of $130 billion by 2030, with new products like Zepbound contributing to this growth.